# reload+after+2024-01-23 18:47:31.991737
address1§614 McKinley Place N.E.
city§Minneapolis
state§MN
zip§55413
country§United States
phone§612 379 8854
fax§612 656 4400
website§https://www.bio-techne.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
fullTimeEmployees§3200
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Charles R. Kummeth', 'age': 63, 'title': 'CEO, President & Director', 'yearBorn': 1960, 'fiscalYear': 2023, 'totalPay': 1259433, 'exercisedValue': 48582008, 'unexercisedValue': 114887408}, {'maxAge': 1, 'name': 'Mr. James T. Hippel', 'age': 52, 'title': 'Executive VP of Finance & CFO', 'yearBorn': 1971, 'fiscalYear': 2023, 'totalPay': 691784, 'exercisedValue': 0, 'unexercisedValue': 22131562}, {'maxAge': 1, 'name': 'Mr. Kim  Kelderman', 'age': 56, 'title': 'Chief Operating Officer', 'yearBorn': 1967, 'fiscalYear': 2023, 'totalPay': 845706, 'exercisedValue': 126845, 'unexercisedValue': 8281222}, {'maxAge': 1, 'name': 'Mr. Shane  Bohnen', 'age': 48, 'title': 'Senior VP, General Counsel & Corporate Secretary', 'yearBorn': 1975, 'fiscalYear': 2023, 'totalPay': 353600, 'exercisedValue': 0, 'unexercisedValue': 291383}, {'maxAge': 1, 'name': 'Mr. William A. Geist', 'age': 53, 'title': 'President of Protein Sciences Segment', 'yearBorn': 1970, 'fiscalYear': 2023, 'totalPay': 533669, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'David  Clair', 'title': 'Senior Director of Investor Relations & Corporate Development', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Gerry  Andros', 'title': 'Vice President of Sales and Marketing', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert M. Gavin', 'age': 55, 'title': 'Vice President of Corporate Development', 'yearBorn': 1968, 'fiscalYear': 2023, 'totalPay': 724512, 'exercisedValue': 0, 'unexercisedValue': 1052351}, {'maxAge': 1, 'name': 'Ms. Brenda S. Everson', 'title': 'Senior VP & Chief Human Resources Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Luca  Cicchetti', 'title': 'Managing Director', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§4
compensationRisk§10
shareHolderRightsRisk§1
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§2
dividendRate§0.32
dividendYield§0.0045
exDividendDate§1699488000
payoutRatio§0.21049999
fiveYearAvgDividendYield§0.45
beta§1.281
priceToSalesTrailing12Months§9.82785
currency§USD
dateShortInterest§1702598400
forwardEps§2.16
pegRatio§4.05
exchange§NMS
quoteType§EQUITY
shortName§Bio-Techne Corp
longName§Bio-Techne Corporation
firstTradeDateEpochUtc§603037800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§0b57ad1b-1e0c-399e-a299-48cc57d56404
gmtOffSetMilliseconds§-18000000
targetHighPrice§95.0
targetLowPrice§65.0
targetMeanPrice§81.09
targetMedianPrice§80.0
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§11
quickRatio§2.765
earningsGrowth§-0.436
grossMargins§0.67806
ebitdaMargins§0.29931
trailingPegRatio§None
